|
1
|
Torre LA, Bray F, Siegel RL, Ferlay J,
Lortet-Tieulent J and Jemal A: Global cancer statistics, 2012. CA
Cancer. 65:87–108. 2015. View Article : Google Scholar
|
|
2
|
Hugen N, van Beek JJ, de Wilt JH and
Nagtegaal ID: Insight into mucinous colorectal carcinoma: Clues
from etiology. Ann Surg Oncol. 21:2963–2970. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Jass JR, Sobin LH and Watanabe H: The
World Health Organization's histologic classification of
gastrointestinal tumors. A commentary on the second edition.
Cancer. 66:2162–2167. 1990. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Kanemitsu Y, Kato T, Hirai T, Yasui K,
Morimoto T, Shimizu Y, Kodera Y and Yamamura Y: Survival after
curative resection for mucinous adenocarcinoma of the colorectum.
Dis Colon Rectum. 46:160–167. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Green JB, Timmcke AE, Mitchell WT, Hicks
TC, Gathright JB Jr and Ray JE: Mucinous carcinoma-just another
colon cancer? Dis Colon Rectum. 36:49–54. 1993. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Catalano V, Loupakis F, Graziano F,
Torresi U, Bisonni R, Mari D, Fornaro L, Baldelli AM, Giordani P,
Rossi D, et al: Mucinous histology predicts for poor response rate
and overall survival of patients with colorectal cancer and treated
with first-line oxaliplatin- and/or irinotecan-based chemotherapy.
Br J Cancer. 100:881–887. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Negri FV, Wotherspoon A, Cunningham D,
Norman AR, Chong G and Ross PJ: Mucinous histology predicts for
reduced fluorouracil responsiveness and survival in advanced
colorectal cancer. Ann Oncol:. 16:1305–1310. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Sengul N, Wexner SD, Woodhouse S, Arrigain
S, Xu M, Larach JA, Ahn BK, Weiss EG, Nogueras JJ and Berho M:
Effects of radiotherapy on different histopathological types of
rectal carcinoma. Colorectal Dis. 8:283–288. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Farhat MH, Barada KA, Tawil AN, Itani DM,
Hatoum HA and Shamseddine AI: Effect of mucin production on
survival in colorectal cancer: A case-control study. World J
Gastroenterol. 14:6981–6985. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Consorti F, Lorenzotti A, Midiri G and Di
Paola M: Prognostic significance of mucinous carcinoma of colon and
rectum: A prospective case-control study. J Surg Oncol. 73:70–74.
2000. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Warschkow R, Tarantino I, Huttner FJ,
Schmied BM, Guller U, Diener MK and Ulrich A: Predictive value of
mucinous histology in colon cancer: A population-based, propensity
score matched analysis. Br J Cancer. 114:1027–1032. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Hyngstrom JR, Hu CY, Xing Y, You YN, Feig
BW, Skibber JM, Rodriguez-Bigas MA, Cormier JN, Chang GJ, et al:
Clinicopathology and outcomes for mucinous and signet ring
colorectal adenocarcinoma: Analysis from the National Cancer Data
Base. Ann Surg Oncol. 19:2814–2821. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
American Cancer Society, . Colorectal
Cancer Facts and Figures 2017–2019Atlanta, GA: 2017
|
|
14
|
Zhang Z: Survival analysis in the presence
of competing risks. Ann Transl Med. 5:472017. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Balachandran VP, Gonen M, Smith JJ and
DeMatteo RP: Nomograms in oncology: More than meets the eye. Lancet
Oncol. 16:e173–e180. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Iasonos A, Schrag D, Raj GV and Panageas
KS: How to build and interpret a nomogram for cancer prognosis. J
Clin Oncol. 26:1364–1370. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Sternberg CN: Are nomograms better than
currently available stage groupings for bladder cancer? J Clin
Oncol. 24:3819–3820. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Scrucca L, Santucci A and Aversa F:
Regression modeling of competing risk using R: An in depth guide
for clinicians. Bone Marrow Transplant. 45:1388–1395. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Compton CC and Greene FL: The staging of
colorectal cancer: 2004 and beyond. CA Cancer J Clin. 54:295–308.
2004. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Noordzij M, Leffondre K, van Stralen KJ,
Zoccali C, Dekker FW and Jager KJ: When do we need competing risks
methods for survival analysis in nephrology? Nephrol Dial
Transplant. 28:2670–2677. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Shen W, Sakamoto N and Yang L:
Melanoma-specific mortality and competing mortality in patients
with non-metastatic malignant melanoma: A population-based
analysis. BMC Cancer. 16:4132016. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Brockman JA, Alanee S, Vickers AJ,
Scardino PT, Wood DP, Kibel AS, Lin DW, Bianco FJ Jr, Rabah DM,
Klein EA, et al: Nomogram predicting prostate cancer-specific
mortality for men with biochemical recurrence after radical
prostatectomy. Eur Urol. 67:1160–1167. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Yang L, Shen W and Sakamoto N:
Population-based study evaluating and predicting the probability of
death resulting from thyroid cancer and other causes among patients
with thyroid cancer. J Clin Oncol. 31:468–474. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Kutikov A, Egleston BL, Wong YN and Uzzo
RG: Evaluating overall survival and competing risks of death in
patients with localized renal cell carcinoma using a comprehensive
nomogram. J Clin Oncol. 28:311–317. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Kattan MW, Heller G and Brennan MF: A
competing-risks nomogram for sarcoma-specific death following local
recurrence. Stat Med. 22:3515–3525. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Charlton ME, Kahl AR, Greenbaum AA,
Karlitz JJ, Lin C, Lynch CF and Chen VW: KRAS testing, tumor
location, and survival in patients with stage IV colorectal cancer:
SEER 2010–2013. J Natl Compr Canc Netw. 15:1484–1493. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
27
|
van Eeghen EE, Bakker SD, van Bochove A
and Loffeld RJ: Impact of age and comorbidity on survival in
colorectal cancer. J Gastrointest Oncol. 6:605–612. 2015.PubMed/NCBI
|
|
28
|
Quirt JS, Nanji S, Wei X, Flemming JA and
Booth CM: Is there a sex effect in colon cancer? Disease
characteristics, management, and outcomes in routine clinical
practice. Curr Oncol. 24:e15–e23. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Majek O, Gondos A, Jansen L, Emrich K,
Holleczek B, Katalinic A, Nennecke A, Eberle A, Brenner H; GEKID
Cancer Survival Working Group, ; et al: Sex differences in
colorectal cancer survival: Population-based analysis of 164,996
colorectal cancer patients in Germany. PLoS One. 8:e680772013.
View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Kang M, Shen XJ, Kim S, Araujo-Perez F,
Galanko JA, Martin CF, Sandler RS and Keku TO: Somatic gene
mutations in African Americans may predict worse outcomes in
colorectal cancer. Cancer Biomark. 13:359–366. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Marmor S, Portschy PR, Tuttle TM and
Virnig BA: The rise in appendiceal cancer incidence: 2000–2009. J
Gastrointest Surg. 19:743–750. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Dulskas A, Poskus T, Poskus E and Strupas
K: Long-term outcomes after surgery for appendiceal mucinous
tumours. Visc Med. 34:151–155. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Venook AP, Niedzwiecki D, Lenz HJ,
Innocenti F, Fruth B, Meyerhardt JA, Schrag D, Greene C, O'Neil BH,
Atkins JN, et al: Effect of first-line chemotherapy combined with
cetuximab or bevacizumab on overall survival in patients with KRAS
wild-type advanced or metastatic colorectal cancer: A randomized
clinical trial. JAMA. 317:2392–2401. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Loupakis F, Ruzzo A, Cremolini C, Vincenzi
B, Salvatore L, Santini D, Masi G, Stasi I, Canestrari E, Rulli E,
et al: KRAS codon 61, 146 and BRAF mutations predict resistance to
cetuximab plus irinotecan in KRAS codon 12 and 13 wild-type
metastatic colorectal cancer. Br J Cancer. 101:715–721. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Salem ME, Weinberg BA, Xiu J, El-Deiry WS,
Hwang JJ, Gatalica Z, Philip PA, Shields AF, Lenz HJ, Marshall JL,
et al: Comparative molecular analyses of left-sided colon,
right-sided colon, and rectal cancers. Oncotarget. 8:86356–86368.
2017. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Mo S, Dai W, Xiang W, Huang B, Li Y, Feng
Y, Li Q, Cai G, et al: Survival contradiction between stage IIA and
stage IIIA rectal cancer. A retrospective study. 9:1466–1475.
2018.
|
|
37
|
Chu QD, Zhou M, Medeiros KL, Peddi P,
Kavanaugh M and Wu XC: Poor survival in stage IIB/C (T4N0) compared
to stage IIIA (T1-2 N1, T1N2a) colon cancer persists even after
adjusting for adequate lymph nodes retrieved and receipt of
adjuvant chemotherapy. BMC Cancer. 16:4602016. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Lee YC, Lee YL, Chuang JP and Lee JC:
Differences in survival between colon and rectal cancer from SEER
data. PLoS One. 8:e787092013. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Bogaert J and Prenen H: Molecular genetics
of colorectal cancer. Ann Gastroenterol. 27:9–14. 2014.PubMed/NCBI
|
|
40
|
Armaghany T, Wilson JD, Chu Q and Mills G:
Genetic alterations in colorectal cancer. Gastrointest Cancer Res.
19–27. 2012.PubMed/NCBI
|
